Baillie Gifford & Co
BMY icon

Baillie Gifford & Co’s Bristol-Myers Squibb BMY Stock Holding History

Baillie Gifford & Co’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-531
Closed -$36.8K – 317
2023
Q1 		$36.8K Buy
531
+73
+16% +$5.15K ﹤0.01% 300
2022
Q4 		$33K Hold
458
– – ﹤0.01% 312
2022
Q3 		$33K Sell
458
-30
-6% -$2.18K ﹤0.01% 303
2022
Q2 		$38K Buy
488
+25
+5% +$1.9K ﹤0.01% 301
2022
Q1 		$34K Buy
463
+36
+8% +$2.42K ﹤0.01% 308
2021
Q4 		$27K Sell
427
-47
-10% -$2.76K ﹤0.01% 339
2021
Q3 		$28K Sell
474
-88
-16% -$5.79K ﹤0.01% 325
2021
Q2 		$38K Sell
562
-45
-7% -$2.93K ﹤0.01% 298
2021
Q1 		$38K Buy
607
+24
+4% +$1.49K ﹤0.01% 293
2020
Q4 		$36K Buy
+583
New +$35.8K ﹤0.01% 283
2017
Q3 		– Sell
-177,742
Closed -$9.9M – 201
2017
Q2 		$9.9M Hold
177,742
– – 0.01% 161
2017
Q1 		$9.67M Sell
177,742
-8,639
-5% -$474K 0.01% 155
2016
Q4 		$10.9M Buy
186,381
+2,596
+1% +$142K 0.02% 153
2016
Q3 		$9.91M Hold
183,785
– – 0.02% 156
2016
Q2 		$13.5M Sell
183,785
-61,640
-25% -$4.36M 0.02% 137
2016
Q1 		$15.7M Sell
245,425
-8,843
-3% -$558K 0.03% 133
2015
Q4 		$17.5M Hold
254,268
– – 0.03% 122
2015
Q3 		$15.1M Sell
254,268
-9,809
-4% -$622K 0.03% 130
2015
Q2 		$17.6M Sell
264,077
-10,344
-4% -$682K 0.03% 119
2015
Q1 		$17.7M Buy
274,421
+144,854
+112% +$9.07M 0.03% 122
2014
Q4 		$7.65M Buy
129,567
+2,860
+2% +$161K 0.02% 158
2014
Q3 		$6.49M Sell
126,707
-6,672
-5% -$333K 0.01% 163
2014
Q2 		$6.47M Sell
133,379
-407,311
-75% -$20.1M 0.01% 168
2014
Q1 		$28.1M Sell
540,690
-12,620
-2% -$672K 0.07% 112
2013
Q4 		$29.4M Buy
553,310
+164,090
+42% +$8.36M 0.07% 108
2013
Q3 		$18M Buy
389,220
+16,244
+4% +$713K 0.05% 121
2013
Q2 		$16.7M Buy
+372,976
New +$16.2M 0.05% 117

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Baillie Gifford & Co's BMY Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 531 shares — an estimated $36.8K sold.

Baillie Gifford & Co first reported a position in BMY in Q2 2013 and held it in 27 quarters. The position peaked at $29.4M in Q4 2013. 2,482 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 531 Bristol-Myers Squibb shares in Q2 2023, an estimated $36.8K.
  • Baillie Gifford & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 27 quarters.
  • Baillie Gifford & Co's Bristol-Myers Squibb position peaked at $29.4M in Q4 2013.
  • 2,482 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.